high5immunology.tv | Rheumatology | EULAR 2023

Spotlight Discussions SpA - ENG

EULAR 2023

Systemic inflammation in SpA /PsA

E. Lubrano, V. Goeb, F. Behrens, A. Askari, F. Ciccia, E. Choy

EULAR 2023

Risk factors and prevention of arthritis

E. Lubrano, V. Goeb, F. Behrens, A. Askari, F. Ciccia, E. Choy

BE COMPLETE, POETYK PSO PROGRAM

EUALR 2023

Treatment opportunities and what is new in PsA

E. Lubrano, V. Goeb, F. Behrens, A. Askari, F. Ciccia, E. Choy

GESPIC, Early (SPACE)-cohort

EULAR 2023

Let's go for early treatment in axial envolvement?

E. Lubrano, V. Goeb, F. Behrens, A. Askari, F. Ciccia, E. Choy

EULAR 2023

Pushing the brake with a new treatment strategy

P. Sewerin, A. Rubbert-Roth, A. Balsa, T. Kvien, F. Behrens

Axial spondyloarthritis 100 sec - ENG

EULAR 2023

Which is the ideal instrument to assess disease…

Ennio Lubrano, MD

GESPIC

EULAR 2023

Factors associated with remission in early peripheral…

Vincent Goeb, MD

Early (SPACE)-cohort

EULAR 2023

Clinically relevant findings for SpA detection

Xenofon Baraliakos, MD

SURPASS

EULAR 2023

The effect of IL-17 inhibition on radiographic…

Xenofon Baraliakos, MD

EULAR 2023

Data from clinical studies relevant for daily practice

Xenofon Baraliakos, MD

EULAR 2023

Do NSAIDs modify the appearance of SIJ MRI?

Xabier Michelena Vegas, MD

Early (SPACE)-cohort

EULAR 2023

What is early axSpA?

Xenofon Baraliakos, MD

EULAR 2023

Definition of early axSpA

Vincent Goeb, MD

EULAR 2023

Secukinumab vs Adalimumab on radiographic progression…

Vincent Goeb, MD

Early (SPACE)-cohort

EULAR 2023

Should we follow chronic back pts. suspected of early…

Xabier Michelena Vegas, MD

Axial spondyloarthritis 100 sec - multi-language

Early (SPACE)-cohort

EULAR 2023

Deberíamos seguir a los pacientes con dolor lumbar…

Xabier Michelena Vegas, MD

GESPIC

EULAR 2023

Facteurs associés à l’obtention d’une rémission dans la…

Vincent Goeb, MD

Early (SPACE)-cohort

EULAR 2023

Was ist frühe axSpA?

Xenofon Baraliakos, MD

SURPASS

EULAR 2023

Effekt der IL-17 Inhibition auf die Röntgenprogression

Xenofon Baraliakos, MD

EULAR 2023

Secukinumab vs Adalimumab dans la progression…

Vincent Goeb, MD

EULAR 2023

Daten aus klinischen Studien für die tägliche Praxis

Xenofon Baraliakos, MD

Early (SPACE)-cohort

EULAR 2023

Klinisch wichtige Befunde zur SpA-Erkennung

Xenofon Baraliakos, MD

EULAR 2023

Los AINES modifican la expresión de la RM de…

Xabier Michelena Vegas, MD

EULAR 2023

Qual'e lo strumento ideale per la valutazione di…

Ennio Lubrano, MD

EULAR 2023

Definition consensuelle ASAS de la spondyloarthrite…

Vincent Goeb, MD

Psoriatic arthritis 100 sec - ENG

RABBIT-SpA

EULAR 2023

No need of MTX again and again and...

Frank Behrens, MD

EULAR 2023

Deucravacitinib - effective and safe

Frank Behrens, MD

SIRENA

EULAR 2023

Early therapy in PsA is predictive

Philipp Sewerin, MD

BE COMPLETE

EULAR 2023

Dual inhibition of IL-17A and IL-17F: a new option in…

Frank Behrens, MD

EULAR 2023

Differences between sex and gender in PsA

Ennio Lubrano, MD

EULAR 2023

Systemic inflammation objectively detectable

Frank Behrens, MD

EULAR 2023

Higher comorbiditiy burden in PsA vs RA

Philipp Sewerin, MD

RABBIT-SPA

EULAR 2023

MTX + Biologica in PsA

Philipp Sewerin, MD

EULAR 2023

Points to consider in PsA!

Philipp Sewerin, MD

Psoriatic arthritis 100 sec - multi-language

RABBIT-SPA

EULAR 2023

MTX + Biologica bei PsA

Philipp Sewerin, MD

EULAR 2023

Mehr Komorbiditäten bei PsA als bei RA

Philipp Sewerin, MD

EULAR 2023

Points to consider bei PsA

Philipp Sewerin, MD

RABBIT-SpA

EULAR 2023

Nicht schon wieder MTX...

Frank Behrens, MD

EULAR 2023

Deucravacitinib - effektiv und sicher

Frank Behrens, MD

EULAR 2023

Sytemische Inflammation objektiv erkennbar

Frank Behrens, MD

SIRENA

EULAR 2023

Frühe Therapie bei PsA prädiktiv

Philipp Sewerin, MD

EULAR 2023

Differenze di genere nell'Artrite Psoriasi

Ennio Lubrano, MD

BE COMPLETE

EULAR 2023

Duale Inhibition A und F: neue Option für PsA

Frank Behrens, MD

Spotlight Discussions RA - ENG

ORAL Surveillance

EULAR 2023

Keeping an eye on the lung!

P. Sewerin, A. Rubbert-Roth, A. Balsa, T. Kvien, F. Behrens

"JAK-POT" study

EULAR 2023

Update on JAKi safety

P. Sewerin, A. Rubbert-Roth, A. Balsa, T. Kvien, F. Behrens

APPIPRA

EULAR 2023

Prevention - should we treat pre-arthitis?

P. Sewerin, A. Rubbert-Roth, A. Balsa, T. Kvien, F. Behrens

EULAR 2023

Putting a focus on TDM

P. Sewerin, A. Rubbert-Roth, A. Balsa, T. Kvien, F. Behrens

EULAR 2023

Pushing the brake with a new treatment strategy

P. Sewerin, A. Rubbert-Roth, A. Balsa, T. Kvien, F. Behrens

Rheumatoid arthritis 100 sec - ENG

APPIPRA

EULAR 2023

Preventing RA

Ernest Choy, MD

EULAR 2023

Peresolimab - a new therapeutic principle in…

Andrea Rubbert-Roth, MD

EULAR 2023

The IL-23 pathway

Ayman Askari, MD

EULAR 2023

Difficult to treat and poly-refractory RA in a clinical…

Alejandro Balsa, MD

EULAR 2023

Pooled safety analysis of filgotinib

Ernest Choy, MD

EULAR 2023

Corticoid bridging in RA - useful and safe

Alejandro Balsa, MD

EULAR 2023

Lung involvement in RA

Ayman Askari, MD

"JAK-POT" study

EULAR 2023

Major adverse cardiovascular events in patients on…

Tore Kvien, MD

EULAR 2023

What is new in RA?

Ayman Askari, MD

Rheumatoid arthritis 100 sec - multi-language

EULAR 2023

Peresolimab - ein neues Therapieprinzip für die…

Andrea Rubbert-Roth, MD

EULAR 2023

AR difícil de tratar y polirrefractaria en la practica…

Alejandro Balsa, MD

EULAR 2023

Tratamiento con glucocorticoides al inicio del FAME -…

Alejandro Balsa, MD

"JAK-POT" study

EULAR 2023

Kardiovaskulære hendelser hos pasienter behandlet med…

Tore Kvien, MD

Arthritis 100 sec - ENG

NOR-DRUM A+B

EULAR 2023

Measurement of anti-drug antibodies in rheumatology

Xenofon Baraliakos, MD

EULAR 2023

Immunogenicity in Adalimumab - real-world data

Tore Kvien, MD

EULAR 2023

Incidence of ILD in patients with RA and PsA

Tore Kvien, MD

EULAR 2023

Development of EMM in SpA patients treated with…

Xabier Michelena Vegas, MD

EULAR 2023

Overview of treatment recommendations in PsA and axSpA

Ennio Lubrano, MD

EULAR 2023

To stop or not to stop TNF-inhibitors after pregnancy…

Francesco Ciccia, MD

EULAR 2023

Arthritis therapy under checkpoint-inhibition

Andrea Rubbert-Roth, MD

Arthritis 100 sec - multi-language

EULAR 2023

Insidens av interstitiell lungesykdom hos pasienter med…

Tore Kvien, MD

EULAR 2023

Therapie der Arthritis unter Checkpoint-Inhibitoren

Andrea Rubbert-Roth, MD

NOR-DRUM A+B

EULAR 2023

Messung von Anti-drug Antibodies in der Rheumatologie

Xenofon Baraliakos, MD

EULAR 2023

Immunogenisitet hos pasienter behandlet med adalimumab…

Tore Kvien, MD

EULAR 2023

Aspetti principali delle raccomandazioni per l'Artrite…

Ennio Lubrano, MD

EULAR 2023

Desarrollo de MEM en pacientes con EspA tratados con…

Xabier Michelena Vegas, MD

EULAR 2023

Interrompere o non interrompere gli anti-TNF dopo la…

Francesco Ciccia, MD

Ankolysing Spondylitis - ENG

EULAR 2023

Childhood infections, perinatal factors, and the risk…

Francesco Ciccia, MD

EULAR 2023

Cardiovascular disease and long-term use of NSAIDs in…

Francesco Ciccia, MD

Ankolysing Spondylitis - multi-language

EULAR 2023

Rischio cardiovascolare e utilizzo prolungato di fans…

Francesco Ciccia, MD

EULAR 2023

Infezioni infantili, fattori perinatali e rischio di…

Francesco Ciccia, MD

Cross-cutting highlights Discussions - ENG

EULAR 2023

New promising strategies in Lupus and Sjögren's…

P. Sewerin, A. Rubbert-Roth, A. Balsa, T. Kvien, F. Behrens

Lupus erythematosus 100 sec - ENG

EULAR 2023

1-year data on CAR-T cell therapy in lupus

Bimba Franziska Hoyer, MD

EULAR 2023

JAK inhibition and BTK-JAK inhibition in lupus

Bimba Franziska Hoyer, MD

EULAR 2023

Update on CAR-T cells!

Andrea Rubbert-Roth, MD

EULAR 2023

Telitacicept in lupus

Bimba Franziska Hoyer, MD

Lupus erythematosus 100 sec - multi-language

EULAR 2023

JAK-Inhibition und BTK-JAK-Inhibition bei Lupus

Bimba Franziska Hoyer, MD

EULAR 2023

1-Jahres Daten zur CAR-T-Zell Therapie beim Lupus

Bimba Franziska Hoyer, MD

EULAR 2023

Telitacicept beim Lupus

Bimba Franziska Hoyer, MD

EULAR 2023

Aktuelles zur CAR-T-Zelltherapie!

Andrea Rubbert-Roth, MD

Sjögren's Syndrome - ENG

EULAR 2023

Telitacicept in Sjögren's Syndrome

Bimba Franziska Hoyer, MD

Sjögren's Syndrome - multi-language

EULAR 2023

Telitacicept beim Sjögren Syndrom

Bimba Franziska Hoyer, MD

Varia 100 sec - ENG

EULAR 2023

IL-17 isoforms in enthesitis

Philipp Sewerin, MD

EULAR 2023

COVID-19: a pandemic with a long tail

Ayman Askari, MD

Varia 100 sec - multi-language

EULAR 2023

IL-17-Isoformen bei Enthesitis

Philipp Sewerin, MD